Dr. John Michael Zajecka, MD

Areas of research

Federal, foundation support and original research2016-2019Principal Investigator, The relationship of changes in Brain Network Activation (BNA) and changes in core depressive and cognitive symptoms, and safety and tolerability, in adult outpatients with major depressive disorder (MDD) treated with open-label, flexible-dose vortioxetine: A proof of concept study (Takeda/Investigator-Initiated Trial)2015-2016Principal Investigator, Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of LY2456302, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (NIMH)2012-2020Principal Investigator, Potential Use of Brain Network Activation (BNA) Analysis Using Evoked Response Potentials to Diagnose Unipolar Major Depression and Bipolar I Depression and Assess Response to Antidepressant Treatment (ElMindA, Ltd.)2010-2014Subinvestigator, A randomized, double-blind, placebo-controlled, parallel-group study of adjunctive mixed salts amphetamine in adult outpatients with major depressive disorder responding inadequately to current antidepressant therapy (Cheryl Herman Foundation)2009-2015Principal Investigator, Prevention of Relapse & Recurrence of Bipolar Depression (NIMH)2004-2005Principal Investigator, "Quetiapine as an Adjunct to SSRIs in the Treatment of Depression" (Investigator-Initiated Trial funded by AstraZeneca)2003-2004Lead Investigator and Principal Investigator, " A Multi-Center Randomized, Double-Blind Study of Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness" (Abbott/Investigator-Initiated Trial)2002-2013Co-Principal Investigator, "Prevention of Recurrence in Depression with Drugs and Cognitive Therapy" (NIMH)2001-2003Subinvestigator, Paroxetine for the Prevention of Pegalated Interferon-Associated Depression in Patients with Chronic Hepatitis C (Glaxo SmithKline/Investigator-Initiated Trial)2001Principal Investigator, A Comparative OMEI Positron Emission Tomography Image Analysis of LY354740 (Eli Lilly/Investigator-Initiated Trial)2000-2004Subinvestigator, A Single Photon Emission Computed Tomography Study of the Effects of Vagal Nerve Stimulation on Regional Cerebral Blood Flow in Patients with Treatment-Resistant Depression (An Appendix to Cyberonics Protocol D-02) (Cyberonics/Investigator-Initiated Trial)2000-2004Principal Investigator, CNS Effects of Sertraline in Depressed Patients (MIICRO Inc./Investigator-Initiated Trial)2000-2004Principal Investigator, Comparison of the CNS Effects (PET) of Acute and Steady Doses of Sertraline in Healthy Volunteers (MIICRO, Inc./Investigator-Initiated Trial)2000-2003Principal Investigator, The Efficacy and Safety of Rapid-Loading Depakote in the Treatment of the Manic Phase of Bipolar Disorder in Adolescents (Abbott/Investigator-Initiated Trial)2000-2003Principal Investigator, Systematic Treatment Enhancement Program for Bipolar Disorder (NIMH/sponsor Massachusetts General Hospital)1999-2001Principal Investigator, A Comparison of the CNS Effects (PET) of Acute Doses of Venlafaxine and Bupropion in Healthy Volunteers (MIICRO, Inc./Investigator-Initiated Trial)1999-2003Principal Investigator, Treatment of Depression in Youths at High Risk for Bipolar Disorder with Bupropion SR and Valproate: An Randomized, Open Comparative Study (Stanley Foundation)1999-2000Principal Investigator, A Comparison of the CNS Metabolic Effects (PET) of Lithobid and Lithonate in Healthy Volunteers (Solvay/MIICRO Inc./Investigator-Initiated Trial)1998-2000Principal Investigator, A Test-Retest Assessment of Metabolic Rate Change Measurements (PET measurement) (MIICRO, Inc./Investigator-Initiated Trial)1997-1998Principal Investigator, Metabolic Imaging for Dose Evaluation in Clinical Trials (NINDS/MIICRO, Inc./Investigator-Initiated)1997Co-Investigator, "Enhancing Recovery in Coronary Heart Disease Patients" (NIH)1991-1994Principal Investigator, "Efficacy and side effect profile of valproic acid versus placebo in panic disorder" (Abbott/Investigator-Initiated Trial)1989-1996Principal Investigator, "Obsessive-compulsive disorder: Evaluation and pharmacological treatment" (Departmental)1988-1995Co-Investigator, "Compassionate treatment with fluvoxamine in outpatients with obsessive-compulsive disorder" (Solvay/Investigator-Initiated)1987-1988Principal Investigator, "Humanitarian use of fluoxetine in depressed patients" (Eli Lilly/Investigator-Initiated)Other Research2021 presentPrincipal Investigator, A Phase II, Multicenter, Randomized, Double-Blind, 12-Week Treatment, 3-Arm, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of RO7017773 in Participants Aged 15 to 45 Years with Autism Spectrum DisorderRoche2021 presentPrincipal Investigator, A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy in Adult Participants with Treatment-resistant DepressionJanssen2021 2022Principal Investigator, A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant TherapyJanssen2021 presentPrincipal Investigator, A Phase 3, Multicenter, Randomized, Double-blind Trial of Fixed-dose Brexpiprazole as Combination Therapy with Sertraline in the Treatment of Adults with Post-traumatic Stress DisorderOtsuka2019 present Principal Investigator, A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects with Treatment-Resistant Depression (LivaNova)2019Principal Investigator, A multi-center, randomized, subject and investigator-blinded, placebo-controlled, active comparator, parallel-group proof of concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of MIJ821 in patients with treatment-resistant depression (Novartis)2019 2020Principal Investigator, A Phase III, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension (Roche)2018 2022Principal Investigator, A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects with Major Depressive Disorder (Sage)2018 2019Principal Investigator, A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Subjects with Major Depressive Disorder (Janssen)2018 2019Principal Investigator, A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) Conducted Globally (Intra-Cellular Therapies, Inc.)2018Principal Investigator, A 6-Month, Multicenter, Double-Blind, Randomized, Flexible-Dose, Parallel-Group Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy (Janssen) 2017-2018Principal Investigator, A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Patients with Major Depressive Disorder with an Inadequate Response to Current Antidepressant Treatment (Taisho)2017 2019 Principal Investigator, A Double-Blind, Placebo-Controlled Study of Brexpiprazole plus Ketamine in Treatment-Resistant Depression (TRD) (Otsuka/Investigator-Initiated Trial)2017 2020Principal Investigator, An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression (Janssen)2017 2018Principal Investigator, A Double-Blind, Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide (Janssen)2017Sub-Investigator, A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects with Treatment-resistant Depression (Janssen)2016 2017Principal Investigator, A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression (Janssen)2016 2017Principal Investigator, A Randomized, Double-Blind, Active-Controlled Trial to Assess the Efficacy and Safety of AXS-05 Administered Orally to Subjects with Treatment Resistant Major Depressive Disorder (Axsome)2016 2017Principal Investigator, A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in Patients with Bipolar I Depression (Allergan)2015-2020Co-Principal Investigator, Establishment of Normative Data of Brain Network Activation Analysis (BNA) Using Evoked Response Potentials, in Adolescents and Young Adults (ElMindA)2015-2017Sub-Investigator, A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering from a Major Depressive Disorder (MDD) and Having Had Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic (Assure Rx)2015-2018Principal Investigator, A Prospective, Longitudinal, Observational Study to Evaluate Potential Predictors of Relapse in Subjects with Major Depressive Disorder Who Have Responded to Antidepressant Treatment (Janssen)2015 2019Principal Investigator, A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder (Takeda)2015-2016Principal Investigator, A multi-center, randomized, double blind, 12-week, parallel group, placebo-controlled, proof of concept study to investigate the efficacy and safety of RO5285119 in individuals with autism spectrum disorders (ASD) (Roche)2014-2016Principal Investigator, A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (Alkermes)2014 2017Principal Investigator , A Phase 3 Multicenter Study of the Long-Term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults Who Have an Inadequate Response to Antidepressant Therapy Alkermes2014-2015Principal Investigator, Phase 2, Randomized, Double-Blind, Multiple-Dose Level, Placebo Controlled, Single Intravenous Dose, Parallel Efficacy and Safety Study of NRX-1074 in Subjects with Major Depressive Disorder (Naurex)2014- 2015Principal Investigator, 191622-135 BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females (Allergan)2013-2016Principal Investigator, A double-blind, placebo-controlled study of cariprazine as adjunctive therapy in major depressive disorder and A phase 3, long-term, open-label study of safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder (Forest)2012-2020Principal Investigator, Potential Use of Brain Network Activation (BNA) Analysis Using Evoked Response Potentials to Diagnose Unipolar Major Depression and Bipolar I Depression and Assess Response to Antidepressant Treatment (ElMindA, Ltd.)2012-2013Principal Investigator, A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase IIb Efficacy and Safety Study of Adjunctive AZD6765 in Patients with Major Depressive Disorder (MDD) and a History of Inadequate Response to Antidepressants (AstraZeneca)2012-2014Principal Investigator, A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of RO4995819 Versus Placebo, as Adjunctive Therapy in Patients with Major Depressive Disorder Having Inadequate Response to Ongoing Antidepressant Treatment (Roche)2012-2014Principal Investigator, A Phase 2, Multicenter, Double-blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant and A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant (Shire)2012-2013Principal Investigator, A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects with Major Depressive Disorder (Takeda)2012-2014Principal Investigator, A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1 mg, 0.4 mg, and 0.8 mg In the Treatment of Acute Depressive Episodes Associated with Bipolar I Disorder in Adult Patients who are on Lithium and/or Valproate and A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL 0.1, 0.4 and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar I Disorder in Adult Patients (Takeda)2011-2012Principal Investigator, A Double-Blind, Paroxetine- and Placebo-Controlled Study of 50 mg/day and 100 mg/day of EB-1010 among Outpatients with Major Depressive Disorder Who have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Antidepressant-Induced Sleepiness, Cognitive Symptoms And/ Or Fatigue During SSRI Treatment of MDD (Euthymics Bioscience, Inc.)2011-2012Principal Investigator, A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder, the Polaris Trial (Otsuka)2011-2012Subinvestigator, A 12-Week, Randomized, Multicenter, Open-Label, Iloperidone (12-24 mg/day), Flexible Dose Study Assessing the Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine, or Aripiprazole (Novartis) 2010-2011Principal Investigator, A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder (Otsuka)2010-2011Principal Investigator, A Randomized Phase 2A, Double-Blind, Placebo-Controlled Study of the Efficacy and safety of CP-601,927 Augmentation of Antidepressant Therapy in Major Depression (Pfizer)2010-2012Principal Investigator A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy and A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Long-Term Safety and Tolerability Study of TC-5214 (S mecamylamine) as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy (AstraZeneca)2010-2012Principal Investigator, A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 20 mg) of LuAA21004 in Acute Treatment of Adults With Major Depressive Disorder (Takeda)2010-2011Principal Investigator, A 52-week, multi-center, open-label study of the safety and tolerability of agomelatine sublingual tablets in patients with Major Depressive Disorder (MDD) (Novartis)2010-2011Principal Investigator, A 12-week, randomized, double-blind, placebo-controlled, phase III safety trial of flibanserin tablets (100 milligrams daily) in women taking a selective serotonin or serotonin-norepinephrine reuptake inhibitor with decreased sexual desire and distress (Boehringer-Ingelheim)2009-2010Principal Investigator, A Placebo-controlled, Double-blind, Parallel-group, Individualized Dosing Study Optimizing Treatment of Adults with Attention Deficit Hyperactivity Disorder to an Effective Response with OROS Methylphenidate (Ortho-McNeil Janssen)2009-2010Principal Investigator, A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed with Major Depressive Disorder (GlaxoSmithKline)2008-2009Subinvestigator, A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults with Generalized Anxiety Disorder (Takeda)2008-2010Principal Investigator, A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy (ADT) among Outpatients with Major Depressive Disorder Who have Responded Inadequately to Prior ADT (Bristol-Myers Squibb)2008-2009Principal Investigator, A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study Comparing the Efficacy and Safety of Lu AA21004 Versus Placebo in Acute Treatment of Adults With Major Depressive Disorder (Takeda)2008-2010Principal Investigator, A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder (Pfizer)2007-2008Principal Investigator, A Multi-Center Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase IIb Proof of Concept Study with 3 Oral Dose Groups of AZD3480 during 12 Weeks Treatment of Cognitive Deficits in Patients with Schizophrenia (AstraZeneca)2007-2009Subinvestigator, A Multicenter, Randomized, Blinded, Controlled, Parallel Group Trial to Demonstrate the Efficacy of rEEG Guided Pharmacotherapy of Patients with Depression Treatment Failure (CNS Response Inc) 2007-2008Principal Investigator, A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia (Cephalon)2006-2007Principal Investigator, Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients (Forest)2006-2009Principal Investigator, An 8-week, randomized, double-blind, fixed-dosage, placebo-controlled, parallel-group, multi-center study of the efficacy, safety and tolerability of agomelatine 25 and 50 mg in the treatment of Major Depressive Disorder (MDD) followed by a 52-week, open-label extension (Novartis)2006-2008Subinvestigator, Duloxetine Versus Placebo in the Long Term Treatment of Patients with Late-Life Major Depression (Eli Lilly)2006-2011Principal Investigator, A Double-Blind, Placebo-Controlled Study of 6(S)-5-MTHF among SSRI-Resistant Outpatients with Major Depressive Disorder (PamLab)2006-2007Principal Investigator, A Placebo-controlled, Double-blind, Parallel-group, Dose Titration Study to Evaluate the Efficacy and Safety of Concerta in Adults with Attention Deficit Hyperactivity Disorder at Doses of 36 mg, 54 mg, 72 mg, 90 mg, or 108 mg per day (McNeil)2006-2007Principal Investigator, An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA at Doses of 36 mg, 54 mg, 72 mg, 90 mg and 108 mg per day in Adults with Attention Deficit Hyperactivity Disorder (McNeil)2006-2015Principal Investigator, Treatment-Resistant Depression Registry (Cyberonics)2006-2007Principal Investigator, A Multi-Centre, Double-Blind, Randomised-Withdrawal, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) As Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilisation Period (AstraZeneca)2005-2006Principal Investigator, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling (Somaxon)2005-2006Principal Investigator, A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety and Tolerability of XBD173 in Patients with Generalized Anxiety Disorder (Novartis)2005Principal Investigator, A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Withdrawal Effects of Chronic Daily and As Needed Dosing With Dapoxetine in the Treatment of Premature Ejaculation (Johnson & Johnson)2004-2006Principal Investigator, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Aripiprazole as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder Bristol-Myers Squibb)2004-2007Principal Investigator, A Multicenter, Long-Term, Open-Label Study to Assess the Safety and Tolerability of Aripiprazole as Adjunctive Therapy in the Treatment of Outpatients With Major Depressive Disorder (Bristol-Myers Squibb)2004-2006Principal Investigator, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole Monotherapy in the Treatment of Acutely Manic Patients with Bipolar I Disorder (Bristol-Myers Squibb)2004-2006Principal Investigator, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients with Bipolar I Disorder with Major Depressive Episode (Bristol-Myers Squibb) 2004-2006Principal Investigator, "A Multicenter, Randomized, Parallel-group, Double-blind, Phase III Comparison of the Efficacy and Safety of Quetiapine Fumarate (oral tablets 400 mg to 800 mg daily in divided doses) to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients" (AstraZeneca)2004-2008Principal Investigator, "A multicenter, open-label, flexible-dose, parallel-group evaluation of the cataractogenic potential of quetiapine fumarate (SEROQUEL) and risperidone (RISPERDAL) in the long-term treatment of patients with schizophrenia or schizoaffective disorder" (AstraZeneca)2003-2005Principal Investigator, "Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients with Major Depression" (Eli Lilly)2003-2004Principal Investigator, "A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Safety and Efficacy of Dapoxetine HCl in the Treatment of Rapid Ejaculation" and "An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation" (Alza)2003-2004Principal Investigator, Augmentation with Aripiprazole to Current Antidepressants in Depressed Patients Who Are Partial Responders (Bristol-Myers Squibb)2002-2003Principal Investigator, "A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Sertraline Versus Venlafaxine XR in the Acute Treatment of Outpatients with Major Depressive Disorder" (Pfizer)2001-2003Principal Investigator, A Double-Blind, Multicenter, Placebo- and Active-Controlled Acute and Extension Study of MK-0869 in the Treatment of Patients With Major Depressive Disorder With Melancholic Features (Merck)2001-2003Principal Investigator, Treatment of Major Depressive Disorder with Psychotic Features with Risperidone Monotherapy; Risperidone and Sertraline; or Haloperidol and Sertraline (Janssen)2001-2003Subinvestigator, Duloxetine Versus Placebo in the Treatment of Fibromyalgia Patients With or Without Major Depressive Disorder (Eli Lilly)2000-2004Principal Investigator, An Acute and Continuation Phase Study of the Comparative Efficacy of Venlafaxine ER (Effexor XR) and Fluoxetine (Prozac) in Achieving and Sustaining Remission (Wellness) in Patients with Recurrent Unipolar Major Depression; Followed by a Long-Term Randomized, Placebo-Controlled Maintenance Treatment Study in Patients Treated Initially with Venlafaxine ER (Wyeth)2000-2001Principal Investigator, A Phase 4, Multicenter, 6-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate Safety and Efficacy of PROVIGIL (Modafinil) at Individually Titrated Doses of 100, 200, 300 or 400 mg/day as Adjunctive Therapy in Patients with Major Depressive Disorder Who Have Demonstrated a Partial Response to Antidepressant Therapy for a Current Major Depressive Episode (Cephalon)2000-2006Principal Investigator, A Multicenter, Pivotal, Safety and Efficacy Study of the NeuroCybernetic Prosthesis System (NCP) in Patients with Depression (Cyberonics, Inc.)2000-2001Principal Investigator, A Double-Blind, Parallel Comparison of Hypericum Extract LI 160 (St. Johns Wort), Fluoxetine and Placebo in Major Depression (Lichtwer Pharma AG)2000-2002Principal Investigator, Open-Label Combination of Olanzapine and Fluoxetine in Major Depressive Disorder (Eli Lilly)2000-2001Principal Investigator, Sustained Efficacy Study of Pregabalin in Patients with Panic Disorder With or Without Agoraphobia (Pfizer) 1999-2004Principal Investigator, A Randomized, Open-Label Comparison of the Efficacy and Safety of Nefazodone vs. Venlafaxine in Outpatients with Generalized Anxiety Disorder (Bristol-Myers Squibb)1999-2000Principal Investigator, Multicenter, Randomized, Double-Blind, Sertraline-Controlled Study of the Efficacy and Safety of Remeron in Subjects with Major Depressive Disorder Who Failed on SSRI Treatment Due to Lack of Efficacy (Organon, Inc.)1999-2000Principal Investigator, A Multicenter, Double-Blind, Placebo and Paroxetine Controlled, Randomized, Flexible Dose Trial of Nefazodone ER in the Treatment of Depressed Patients (Bristol-Myers Squibb)1999-2000Principal Investigator, A Multicenter, Double-Blind, Double-Dummy Placebo and Lithium-Controlled, Randomized, Flexible-Dose Evaluation of the Safety and Efficacy of Lamotrigine in the Long-Term Prevention of Relapse and Recurrence of Mania and/or Depression in Patients with Bipolar I Disorder (Glaxo Wellcome)1998-2000Principal Investigator, A Double-Blind, Multicenter, Dose-Finding Acute and Extension Study of L-759,274 versus Paroxetine Hydrochloride and Placebo in the Treatment of Outpatients with Major Depressive Disorder (Merck)1998-2000Principal Investigator, Olanzapine Versus Divalproex in the Treatment of Acute Mania (Eli Lilly)1998-2000Principal Investigator, Fluoxetine Versus Placebo in Posttraumatic Stress Disorder (Eli Lilly)1998-2000Principal Investigator, A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Fixed-Dose Evaluation of the Safety and Efficacy of Lamotrigine in the Long-Term Prevention of Relapse and Recurrence of Depression and/or Mania in Patients with Bipolar I Disorder (Glaxo Wellcome)1998-2000Principal Investigator, A Double-Blind, Placebo and Haloperidol-Controlled, Multicenter Study Evaluating the Efficacy and Safety of SR 142801 in Schizophrenic Patients (Sanofi)1998-2000Principal Investigator, A Double-Blind, Placebo and Haloperidol-Controlled, Multicenter Study Evaluating the Safety and Efficacy of SR 141716 in Schizophrenic Patients (Sanofi)1998-2001Principal Investigator, Reboxetine Versus Placebo and Fluoxetine in a Controlled, Randomized, Double-Blind, Multicenter Study of Treatment in Major Depressive Disorders (Pharmacia & Upjohn)1998-1999Principal Investigator, A Phase III, Randomized, Placebo-Controlled Study Evaluating the Safety and Outcome of Treatment with Oral Ziprasidone in Subjects with Mania and An Open Extension Study Evaluating the Safety and Outcome of 40-160 mg Daily of Oral Ziprasidone in the Treatment of Subjects Who Have Participated in Protocol 601 (Pfizer)1998-2000Principal Investigator, An Open-Label Evaluation of the Efficacy, Safety and Dosing of Citalopram in Outpatients with Depression (Forest Laboratories)1997-1998Principal Investigator, An Eight-Week, Double-Blind, Placebo-Controlled Study of 2, 20, 50 and 100 mg Flibanserin b.i.d. and Paroxetine q.d. in Patients with Major Depressive Disorder (Boehringer-Ingelheim)1997-1999Principal Investigator, A Multicenter, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Evaluation of the Safety and Efficacy of Lamotrigine in the Long-Term Prevention of Mood Episodes in Patients with Bipolar Disorder with Rapid Cycling: Incorporating Participation in Genotype Research (Glaxo Wellcome)1997Co-Investigator, The Effects of LY354740 on Regional Cerebral Glucose Metabolism Measured with Positron Emission Tomography in Healthy Subjects (Eli Lilly) 1997-1998Principal Investigator, Remerons Efficacy in Subjects with Major Depressive Disorder Who Are SSRI Selective Serotonin Reuptake Inhibitor) Treatment Failures (Organon Inc.)1997-1998Co-Investigator, The Efficacy and Safety of Rapid-Loading Depakote in the Treatment of Acutely Manic Patients with Bipolar Disorder (Abbott)1997Co-Investigator, Olanzapine Versus Placebo in the Treatment of Mania Associated with Bipolar I Disorder (Eli Lilly)1996-1997Principal Investigator, Fluoxetine vs. Sertraline and Paroxetine in Major Depression: Comparison of Discontinuation-Emergent Signs and Symptoms (Eli Lilly)1996-2000Co-Investigator, A Prospective, Multi-Center Study Comparing the Safety and Efficacy of Serzone (Nefazodone HCl) to Cognitive Behavioral Therapy )(CBT-CD) and Combined Serzone and CBT-CD for the Acute, Continuation and Maintenance Treatment of Chronic Major Depression and Double Depression (Bristol-Myers)1996-1997Principal Investigator, Double-Blind, Placebo-Controlled Study of Venlafaxine and Fluoxetine in Outpatients with Major Depression (Wyeth-Ayerst)1996-1998Principal Investigator, Gabapentin Adjunctive Treatment in Patients with Bipolar Disorder (Parke-Davis)1995-1998Co-Investigator, A Multicenter, Open, Randomized Comparison of ICI 204,636 (Seroquel) and Usual Care on Health Outcomes in Subjects with Schizophrenia and Schizoaffective Disorder (AstraZeneca)1995-1997Principal Investigator, "Double-blind, placebo-controlled, parallel-group, comparative study of venlafaxine and fluoxetine in depressed outpatients to measure onset of clinical activity" (Wyeth-Ayerst)1995-1997Principal Investigator, "Fluoxetine vs. placebo in OCD relapse prevention" (Eli Lilly)1995-1996Principal Investigator, "A multicenter, placebo-controlled study of relapse-prevention by long-term treatment with high or low doses of ORG 4428 in outpatients with recurrent major depressive episode" (Organon Inc.)1995Principal Investigator, "The efficacy of buspirone potentiation in poor or partial responders to the antidepressant effect of nefazodone" (Bristol-Myers Squibb)1995Principal Investigator, "A prospective, multicenter, open-label study of Serzone (nefazodone) in the management of patients with symptoms of depression in general psychiatric practices" (Bristol-Myers Squibb)1994-1995Co-Principal Investigator, "A double-blind, placebo-controlled dose escalation study of the safety and efficacy of oral ondansetron in the treatment of patients with panic disorder" (Glaxo)1994-1996Principal Investigator, "Risperidone QD vs. BID dosing in schizophrenia: a double blind, parallel group, phase III multicenter study" (Janssen Research)1994-1995Principal Investigator, "Establishment of oral flesinoxan dose effect relationships for efficacy and safety: A randomized, double-blind, parallel group, placebo-controlled, multi-center study in outpatients with major depressive disorder" (Solvay)1994-1995Principal Investigator, "Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders" (Eli Lilly)1994-1996Principal Investigator, "Sertraline treatment followed by a double-blind comparison of sertraline and placebo in the prevention of relapse in outpatients with obsessive-compulsive disorder" (Pfizer)1994-1995Principal Investigator, "A double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression" (SmithKline Beecham Pharmaceuticals)1993-1995Principal Investigator, "A double-blind, comparative, placebo-controlled trial of paroxetine in the prevention of recurrent depression" (SmithKline Beecham Pharmaceuticals)1993-1995Co-Investigator, "A phase II, multicenter, randomized, parallel-group, double-blind, dose-finding study of 3 different doses of roxindole versus placebo in outpatients suffering from depression" (EM Industries, Inc., Pharmaceutical Division)1993-1994Principal Investigator, "Safety surveillance study for wellbutrin sustained release" (Burroughs Wellcome Co.)1993-1996Co-Investigator, "Double-blind comparison of sertraline and imipramine in outpatients with concurrent major depression and dysthymia" (Pfizer)1993-1996Co-Investigator, "Double-blind parallel comparison of sertraline and imipramine in outpatients with chronic major depression" (Pfizer)1993-1995Principal Investigator, "A double-blind trial comparing nefazodone to fluoxetine in patients with activation side effects previously demonstrated during treatment with fluoxetine for major depression" (Bristol-Myers Squibb)1993-1995Principal Investigator, "A multi-center, double-blind, randomized trial comparing the effects of nefazodone to sertraline on sexual function in patients with previously demonstrated sexual dysfunction with sertraline during treatment for major depression" (Bristol-Myers Squibb)1993-1995Principal Investigator, "Six month open-label evaluation of safety and efficacy of venlafaxine followed by randomized, double-blind, placebo-controlled one year evaluation of venlafaxine in the prophylactic treatment of recurrent major depression" (Wyeth-Ayerst)1993-1994Co-Investigator, "A randomized, double-blind, placebo-controlled study of the safety and efficacy of two doses of ondansetron versus placebo in the treatment of social phobia" (Glaxo)1992-1994Principal Investigator, "An open multicenter trial of nefazodone in the treatment of patients with treatment refractory depression" (Bristol-Myers)1992-1994Principal Investigator, "Amesergide/fluoxetine/placebo in major depression" (Eli Lilly)1992-1994Co-Investigator, "A double-blind response study to determine the safety and efficacy of fixed doses (75-900 mg/day) of moclobemide in patients with panic disorder with and without agoraphobia" (Hoffmann-LaRoche)1992-1995Co-Investigator, "Sertraline treatment of adolescent outpatients with major depression" (Pfizer)1992-1994Principal Investigator, "Double-blind comparison of sertraline and desipramine in outpatients with concurrent major depression and obsessive-compulsive disorder (Pfizer)1992-1993Principal Investigator, Double-Blind, Placebo-Controlled, Parallel-Group Dosage Comparison Study of BID and TID Dosing of Venlafaxine in Outpatients with Major Depression (Wyeth-Ayerst)1991-1993Principal Investigator, "Multicenter Trial to Evaluate the Efficacy and Safety of Sertraline in the Treatment of Major Depression" (Roerig)1991-1992Principal Investigator, "Zatosetron in patients with generalized anxiety disorder" (Eli Lilly)1991-1992Principal Investigator, "A prospective, randomized, double-blind placebo-controlled multi-center, parallel groups comparison of the efficacy and safety of abecarnil (7.5-17.5 mg) and diazepam (15-35 mg) in outpatients with generalized anxiety disorder" (Sandoz Pharmaceuticals)1991-1992Principal Investigator, "Fluoxetine versus placebo in major depressive disorder: Influence of REM sleep latency" (Eli Lilly)1991-1994Principal Investigator, "Paroxetine versus clomipramine and placebo in the treatment of obsessive-compulsive disorder" (SmithKline Beecham Pharmaceuticals)1991-1993Principal Investigator, "Double-blind comparison of sertraline, clomipramine and placebo in outpatients with obsessive-compulsive disorder" (Pfizer)1991-1992Principal Investigator, "A double-blind randomized controlled evaluation of the effects of venlafaxine on the blood pressure of patients being treated for major depression" (Wyeth-Ayerst)1991-1992Co-Investigator, "Double-blind comparison of 3 fixed doses of tandospirone and placebo in outpatients with major depression" (Pfizer)1991-1992Primary Investigator, "Paroxetine versus fluoxetine in outpatients with major depression" (SmithKline Beecham)1990-1993Principal Investigator, "A double-blind long-term safety study comparing remoxipride and haloperidol in schizophrenic outpatients" (Merck Sharp & Dohme)1990-1991Principal Investigator, "Fixed-dose, double-blind study comparing efficacy and safety of Xanax-SR tablets vs. placebo in the treatment of panic disorder using once daily dosing" (Upjohn)1990-1993Principal Investigator, "A triple-blind parallel study comparing two dose ranges of haloperidol in hospitalized patients with schizophrenia" (Merck Sharp & Dohme)1990-1992Principal Investigator, "Fluoxetine vs. placebo: Long-term treatment of major depression" (Eli Lilly)1990-1992Co-Principal Investigator, "A double-blind multi-center trial of nefazodone, fluoxetine and placebo in the treatment of depressed outpatients" (Bristol-Myers)1989-1990Principal Investigator, "Treatment use of Anafranil in obsessive-compulsive disorder" (Ciba-Geigy)1989-1991Co-Investigator, "The efficacy and safety of a combination of fluoxetine and deracyn" (Upjohn)1989-1990Co-Investigator, "Collaborative fixed-dose study of the efficacy and safety of deracyn-SR tablets in panic disorder with agoraphobia" (Upjohn)1988-1994Co-Investigator, "An open-label evaluation of the long-term safety and clinical acceptability of oral venlafaxine in depressed outpatients" (Wyeth-Ayerst)1988Co-Investigator, "Prospective open evaluation of the seizure incidence with bupropion hydrochloride (Wellbutrin) (Burroughs-Wellcome)1988Co-Investigator, "A multicenter randomized double-blind parallel group dose response of milacemide in patients with mood disorders currently in a major depressive episode" (. D. Searle)1988-1990Co-Investigator, "Double-blind comparison of SM-3997 (tandospirone) and placebo in outpatients with depression" (Pfizer)1988-1990Co-Investigator, "Fluvoxamine in the treatment of panic disorder: A multicenter double-blind placebo-controlled study in outpatients" (Reid-Rowell)1987-1990Co-Investigator, "Fluvoxamine in the treatment of depression: A multicenter double-blind placebo-controlled comparison with desipramine in outpatients" (Reid-Rowell) 1987Co-Investigator, "Tomoxetine versus placebo - fixed-dose study in depressed outpatients" (Eli Lilly)1987-1990Co-Investigator, "Nefazodone versus placebo in depressed outpatients: A multi-center double-blind comparison of four fixed doses of nefazodone" (Bristol-Myers)1986-1988Research Investigator, National Vietnam Veteran Study (Research Triangle Institute, South Carolina)1985-1988Co-Investigator, "Fluoxetine versus amitriptyline in depressed adult patients" (Eli Lilly)1984-1985Medical Consultant and Intake Screening, "A multicenter (5), double-blind placebo-controlled, fixed-dose study evaluating the efficacy of cyclospasmol (Cyclandelate) in primary degenerative dementia or multi-infarct dementia" (Ives Laboratories)1979The effects of dexamethasone on post-electroconvulsive therapy memory impairment in laboratory mice" (senior research project Marquette University)